CFO
HRMY icon

Callan Family Office’s Harmony Biosciences HRMY Stock Holding History

Callan Family Office’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$585K Buy
16,054
+470
+3% +$14.8K 0.01% 765
2026
Q1 		$437K Buy
15,584
+2,359
+18% +$77.4K 0.01% 816
2025
Q4 		$495K Buy
13,225
+5,821
+79% +$191K 0.01% 786
2025
Q3 		$204K Sell
7,404
-4,209
-36% -$145K 0.01% 821
2025
Q2 		$367K Buy
+11,613
New +$374K 0.01% 705

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Callan Family Office's HRMY Position: Q2 2026 in Review

Callan Family Office increased its Harmony Biosciences (HRMY) stake by 3% in Q2 2026, buying an estimated $14.8K and bringing the position to 16,054 shares worth $585K. The position accounts for 0.01% of the portfolio, ranked #765.

Callan Family Office first reported a position in HRMY in Q2 2025 and has held it in 5 quarters since. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Callan Family Office held 16,054 shares of Harmony Biosciences worth $585K as of Q2 2026.
  • Callan Family Office bought 470 Harmony Biosciences shares in Q2 2026, an estimated $14.8K.
  • Harmony Biosciences made up 0.01% of Callan Family Office's portfolio in Q2 2026, its #765 holding.
  • Callan Family Office first reported a position in Harmony Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.